On Monday, U.S. Silica Holdings Inc (NYSE:SLCA)’s shares declined -3.18% to $29.87.
U.S. Silica Holdings Inc (SLCA) declared that members of the administration team will take part in the following investor conferences during the second quarter of 2015:
William Blair & Company 2015 Growth Stock Conference
June 9, 2015
Four Seasons Hotel – Chicago, IL
Oppenheimer Energy 1-on-1 Conference 2015
June 9, 2015
Sofitel Hotel – New York, NY
Barclays High Yield Bond & Syndicated Loan Conference
June 11, 2015
The Broadmoor – Colorado Springs, Colorado
Administration will meet with institutional investors throughout these events. Please note, when applicable, the presentations will be posted on the Company’s website prior to the start of each event at www.ussilica.com.
U.S. Silica Holdings, Inc. produces and sells commercial silica in the United States. It operates through two segments, Oil & Gas Proppants, and Industrial & Specialty Products. The company offers whole grain commercial silica products to be used as fracturing sand in connection with oil and natural gas recovery, in addition to sells its whole grain silica products in various size distributions, grain shapes, and chemical purity levels for manufacturing glass products.
Boyd Gaming Corporation (NYSE:BYD)’s shares gained 3.35% to $14.79.
Boyd Gaming Corporation (BYD) declared that following the terms of its formerly declared tender offer and consent solicitation for any and all of its outstanding 9.125% Senior Notes due 2018 (the “Notes”), holders of about $458.7 million aggregate principal amount of the outstanding Notes (about 91.7% of the outstanding Notes), have validly tendered their Notes and are deemed to have validly delivered the requisite consents for the projected amendments to the indenture governing the Notes prior to the expiration of the consent date which was 5:00 p.m., New York City time, on May 21, 2015.
The consents received exceeded the number needed to approve the projected amendments. The terms of the tender offer and consent solicitation are detailed in the Company’s offer to purchase and consent solicitation statement, dated as of May 7, 2015. Based on the consents received, the Company, the guarantors party to the indenture governing the Notes and the trustee under the indenture governing the Notes have reached a supplemental indenture that, among other modifications, eliminates substantially all of the restrictive covenants in the indenture.
Boyd Gaming Corporation, together with its auxiliaries, operates as a multi-jurisdictional gaming company. It operates in five segments: Las Vegas, Downtown Las Vegas, Midwest and South, Peninsula, and Borgata. The company owns and operates 21 gaming entertainment properties located in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, and New Jersey.
At the end of Monday’s trade, GrafTech International Ltd (NYSE:GTI)‘s shares dipped -0.39% to $5.05.
GrafTech International Ltd (GTI) declared it has entered into an investment agreement with an associate of Brookfield Asset Administration Inc. under which Brookfield will acquire $150 million of 7% convertible preferred shares of GrafTech in a private offering. The investment agreement follows the letter of intent declared by GrafTech on April 29, 2015.
The convertible preferred share issuance, which was unanimously approved by GrafTech’s Board of Directors, is predictable to close once customary closing conditions, counting applicable regulatory approvals, are satisfied.
Under the terms of the investment agreement, upon issuance, the convertible preferred shares will be issued in two series, Series A shares and Series B shares. The series A shares will be right away convertible into GrafTech common shares equal to about 19.9% of the presently outstanding shares of GrafTech common stock, at a conversion price of $5.00 per common share, subject to customary anti-dilution adjustments. The series B shares will become convertible into common shares equal to about 2% of the presently outstanding shares only upon approval by GrafTech stockholders in accordance with New York Stock Exchange requirements. If approved, the two series will be combined into one series.
GrafTech International Ltd. manufactures and sells graphite and carbon material science-based solutions. It operates through two segments, Industrial Materials and Engineered Solutions.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), ended its Monday’s trading session with 6.40% gain, and closed at $21.12.
Momenta Pharmaceuticals, Inc. (MNTA) a biotechnology company specializing in the characterization and engineering of complex drugs, will present updated data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane(R)) and gemcitabine (GEM) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) at the 2015 ASCO Annual Meeting, recently from 8:00 to 11:30 am CDT (Abstract #4114).
Necuparanib was administered daily in combination with 125 mg/m2 nabP and 1000 mg/m2 GEM (Days 1, 8, and 15 of each 28-day cycle). The necuparanib starting dose was 0.5 mg/kg, which was raised via a modified 3+3 design until a maximum tolerated dose (MTD) was determined. nabP was added to the treatment regimen starting with Cohort 3. Thirty-nine patients (12 patients in the first two cohorts and 27 patients in the five subsequent cohorts) received necuparanib and were comprised of in the analyses. Top-line results comprised of:
- Adding necuparanib to GEM or nabP + GEM did not appear to enhance the incidence, severity, or duration of the predictable AEs associated with these regimens. The most common (>=30% of patients) AEs were anemia (56%), fatigue (51%) neutropenia (46%), leukopenia (36%), nausea (36%), thrombocytopenia (36%) and ALT raised (31%). Two patients had dose-limiting toxicities: AST/ALT raised at 0.5 mg/kg and cellulitis at injection site at 6 mg/kg necuparanib. There were mild aPTT enhances at 4-6 mg/kg necuparanib.
- 5 mg/kg necuparanib was determined to be the MTD and the recommended Phase 2 dose.
- Encouraging signals of activity were observed:
- For the 24 patients in cohorts 3-7 who received at least one dose of necuparanib + nabP + GEM, the median overall survival (OS) was 14.2 (95% CI, 9.3-16.0) months.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
